Phase III 2026 Research (8)
8 papers in the Phase III 2026 topic, indexed by PF-Atlas from PubMed and global journals.
- Biomarker profiles in idiopathic and progressive pulmonary fibrosis after LPA antagonism: exploratory analysis from a phase 2 trial of admilparant. · Respiratory research · 2026
- Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. · The New England journal of medicine · 2026
- Combined results of the TETON-1 and TETON-2 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. · American journal of respiratory and critical care medicine · 2026
- [Treatment of pulmonary fibrosis: Beginning of a new era]. · Pneumologie (Stuttgart, Germany) · 2026
- Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis. · The New England journal of medicine · 2026
- Study Design and Rationale for the TETON-PPF Phase 3, Randomized, Controlled Clinical Trial of Inhaled Treprostinil in the Treatment of Progressive Pulmonary Fibrosis. · CHEST pulmonary · 2025
- Efficacy and Safety of Admilparant, an LPA Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. · American journal of respiratory and critical care medicine · 2025
- Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis. · BMJ open respiratory research · 2022
Medical disclaimer. Research listings are for information only and are not medical advice.